With Novartis and Google jumping in, Medicxi unveils a $300M late-stage biotech fund with a transatlantic scope
The European venture group Medicxi is staking out some new terrain in biotech investing. And they’re bringing in two big players — Novartis and Google’s Verily — as key backers.
Known for a longtime strategy that clearly and carefully concentrates their attention on single-asset organizations that start out early on a limited budget, Medicxi has added a new, $300 million fund that will focus on late-stage biotech investments. But they still want to fall in love with a top drug before they buy in.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
